All In Biotech

Drug Trial Radar · NCT04066231

ANTERO-4: VIPUN Gastric Monitoring System in an Erythromycin Model

ANTERO-4: A Clinical Investigation of the Effects of Erythromycin on Gastric Motility, Assessed With the VIPUN Gastric Monitoring System in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Aug 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

5

Actual

Start

Sep 7, 2019

Primary completion

Mar 10, 2020

Study completion Mar 10, 2020

Sponsor

Lead sponsor
Prof Dr Jan TackAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

It has been demonstrated that the VIPUN Gastric Monitoring System (GMS) can discriminate healthy physiological and pharmacologically-inhibited gastric motility, using a codeine-model in healthy adults (S60320 / AFMPS80M0687). Erythromycin is a gastroprokinetic agent, known to stimulate gastric contractility. A single dose of 200 mg erythromycin has been shown to induce a prolonged period of enhanced phasic contractile activity. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults. The performance of the VIPUN GMS can be enhanced by data-driven optimization of the VIPUN Motility Algorithm, used to quantify gastric motility.

Conditions

  • Gastric Motility

Interventions

  • VIPUN GMSDevice

    Motility is measured for 4 hours with the VIPUN Gastric Monitoring System (GMS).

  • Erythromycin LactobionateDrug

    Test model: Erythromycin has gastroprokinetic properties. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults. Erythromycin Lactobionate infusion: 200 mg i.v. infusion over a period of 20 minutes. Note: Erythromycin is not labeled as a gastroprokinetic agent in Belgium.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GBMI baselineTime frame: t = 0 - 119 minutes
  2. GBMI120 - 139Time frame: t = 120 - 139 minutes

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UZ Leuven

    Leuven, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.